SLC5A2 and type 2 diabetes mellitus: Xing et al. also conducted a meta-analysis of six RCTs [41], involving 309 patients with NAFLD and T2DM and concluded that SGLT-2 inhibitors significantly reduced ALT and liver fat content, consistent with our research results, confirming the reliability of our research results.